The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:Fink Bets On a Healthcare Startup Not Rated 0.0 Email Routing List Email & Route  Print Print
Tuesday, January 29, 2019

Fink Bets On a Healthcare Startup

News summary by MFWire's editors

The man leading the world's largest asset manager is also betting on a healthcare startup.

Laurence D. Fink
Chairman, CEO
Larry Fink, CEO of BlackRock [profile], is one of the individual investors backing Seattle-based 98point6, CNBC reports. 98point6 has raised $86.3 million in funding so far, according to Crunchbase, and that includes a $50-million series C last October led by Goldman Sachs' merchant banking division. Other individual 98point6 investors include: Nadeer Naini (managing partner of Frazier Healthcare Partners); Jim Sinegal (founder and ex-CEO of Costco); and David Viniar (former chief financial officer of Goldman).

98point6's leadership includes CEO Robbie Cape (a Microsoft alumnus) and product chief Rob Schwietzer (ex-chief of Amazon Prime). The startup offers a subscription messaging service for doctors and patients.

The article does not hint at how much money Fink put into 98point6. Last April Fink's net worth famously crossed the $1 billion mark, though it may have slipped since then given that BlackRock's stock price is down about 23 percent since then. 

Edited by: Neil Anderson, Managing Editor

Stay ahead of the news ... Sign up for our email alerts now

 Do You Recommend This Story?

Return to Top
 News Archives
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Add to My Yahoo!
follow us in feedly

©All rights reserved to InvestmentWires, Inc. 1997-2021
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use